Pfizer, NNPA, and
Education and Awareness
(NNPA), and scholars from
a new national poll designed to deepen understanding and gauge
perceptions around sickle cell disease (SCD) among African Americans.
The poll, which included responses from adults in the US who
self-identified as African American, revealed that while the majority of
respondents were familiar with SCD and understood the disease in
general, only one-third (36%) were aware that it
disproportionately affects people of African descent,1
demonstrating a critical need for education and awareness.
Sickle cell disease is a lifelong and debilitating disorder that affects
red blood cells.2 It is the most common inherited blood
disorder in the US, and most people living with sickle cell disease are
of African descent.3 In fact, SCD occurs in one out of every
365 African American births.4
“These poll findings will give our readers an in-depth understanding of
how sickle cell disease is perceived by African Americans,” said Dr.
African American-owned community newspapers from around the US. “With
this knowledge from the dedicated research team at
and through our collaboration with Pfizer, we can spur meaningful
conversation and assess the best ways to improve disease education for
those impacted in our communities.”
The poll also revealed:
Despite long-standing historical perceptions of mistrust in medical
professionals by the African American community, in this poll 91%
of respondents indicated that they believed health care
professionals to be trustworthy.1
Over three quarters (79%) of respondents described SCD
as “more important” or “just as important” as other health conditions.1
Most respondents (76%) had positive or neutral
attitudes toward SCD clinical trials and a majority indicated a
willingness to participate in future clinical trials for SCD, given
appropriate knowledge and recommendations from health care
Historically, clinical trial recruitment obstacles have been a
barrier in SCD research. In a review of 174 SCD trials, difficulty
enrolling patients was the stated cause in nearly half of the
trials that terminated early.5
The majority (79%) of respondents understood the importance
of disease education and expressed the need for additional current
information, specifically regarding pain relief, clinical trials, and
progress toward better treatment or a cure.1
“We are encouraged by the poll results as they have allowed us to gain a
better understanding of the perceptions of SCD among African Americans.
These insights will not only help us determine how to further enhance
disease education and awareness, but will also help us educate SCD
patients and their families about the importance of clinical trials in
bringing novel treatment options to market for those in need,” said Dr.
our work with patients and the community, as well as through research
and development and clinical trials, Pfizer remains committed to
addressing the unmet needs of people affected by sickle cell disease.”
The poll is a key initiative under the Pfizer-NNPA collaboration.
Throughout the rest of 2017, a series of articles with more information
regarding SCD, its impact, as well as the common myths, is also being
published in NNPA-affiliated newspapers. The poll results and
information about SCD will be shared with the NNPA network and
incorporated into future educational programs. More information about
SCD can be found at www.Pfizer.com/RareDisease.
For more information about the NNPA, please visit www.nnpa.org.
About the Poll
The National Poll of African Americans on Sickle Cell Disease
Awareness questionnaire was conducted via a telephone interviewing
system by the
were completed, drawing from 31,934 telephone calls made that resulted
in polling answers from 741 individuals aged 20–70 living across the US,
who identified as being of African American ethnicity. Poll respondents
were selected from individuals who had agreed to participate in the
survey through the
Results are weighted to the African American population projected by the
Census in the
nationally representative survey of the African American population to
accurately measure the knowledge, perceptions, and behavior of the
community with regard to sickle cell disease.
Pfizer Rare Disease
Rare disease includes some of the most serious of all illnesses and
impacts millions of patients worldwide,6 representing an
opportunity to apply our knowledge and expertise to help make a
significant impact on addressing unmet medical needs. The Pfizer focus
on rare disease builds on more than two decades of experience, a
dedicated research unit focusing on rare disease, and a global portfolio
of multiple medicines within a number of disease areas of focus,
including hematology, neuroscience, and inherited metabolic disorders.
Pfizer Rare Disease combines pioneering science and deep understanding
of how diseases work with insights from innovative strategic
collaborations with academic researchers, patients, and other companies
to deliver transformative treatments and solutions. We innovate every
day leveraging our global footprint to accelerate the development and
delivery of groundbreaking medicines and the hope of cures.
to learn more about our Rare Disease portfolio and how we empower
patients, engage communities in our clinical development programs, and
support programs that heighten disease.
Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and like us on
The NNPA is a national trade association of 211 Black and women-owned
U.S. media companies with a weekly print and digital readership of over
20.1 million Black Americans.
old. The NNPA is known as the
Black America, because its member publishers are trusted, respected and
embedded in their local communities where they provide significant
influence and impact. Learn more about the NNPA.org.